Patrys (ASX:PAB) Current Accrued Expense : A$0.00 Mil (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Patrys Current Accrued Expense?

Patrys's Current Accrued Expense for the quarter that ended in Dec. 2023 was A$0.00 Mil.

Patrys Current Accrued Expense Historical Data

The historical data trend for Patrys's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Patrys Current Accrued Expense Chart

Patrys Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Current Accrued Expense

Get a 7-Day Free Trial

Patrys Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Current Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

Patrys Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Patrys Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Patrys's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Patrys (ASX:PAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Patrys Ltd (ASX:PAB) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Level 4, 100 Albert Road, South Melbourne, Melbourne, VIC, AUS, 3205

Website

https://www.patrys.com

Patrys Ltd focuses on the development of natural human antibody-based therapies for the treatment of cancer. The company's product includes Deoxymab 3E10, PAT-SC1, PAT-DX1 PAT-DX1-NP, PAT-DX3, and PAT-LM1. Its main technology is Deoxymab 3E10, a DNA damage repair (DDR) antibody that penetrates live cell nuclei and inhibits key mechanisms of DNA repair in target cancer cells.